Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daily aspirin for fibrosis progression in metabolic dysfunction-associated steatotic liver disease
TCTR20230705001Phase 3Completed
- Sponsor
- Phramongkutklao Hospital
- Start
- Oct 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aspirin in metabolic dysfunction-associated steatotic liver disease (MASLD), hepatic fibrosis, sponsored by Phramongkutklao Hospital. Started Oct 2020; status: completed.
02
Drugs
aspirin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)hepatic fibrosis
Beyond the preview
Go deeper on TCTR20230705001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230705001.